Table 4.
Andersen-Gill regression model with the endpoint EFS analysed on a per-protocol basis
| HR | 95 % CI | p value | |
|---|---|---|---|
| Genetic risk according to ELN | |||
| Favorable risk | 0.38 | 0.31–0.47 | <0.0001 |
| Intermediate-2’ | 1.05 | 0.86–1.29 | 0.63 |
| Adverse risk | 1.79 | 1.48–2.17 | <0.0001 |
| s/t-AML | 1.28 | 1.04–1.58 | 0.018 |
| Gender (male) | 1.35 | 1.17–1.56 | <0.0001 |
| WBC (median-dichotomized)* | 1.27 | 1.10–1.47 | 0.001 |
| Valproic acid | 1.22 | 1.02–1.47 | 0.032 |
| Allogeneic HCT in 1st CR | 0.47 | 0.37–0.59 | <0.0001 |
| ATRA | 0.88 | 0.76–1.01 | 0.07 |
Variables excluded after limited backward selection in the order of their exclusion: DNMT3A mutational status (p= 0.87), ASXL1 mutational status (p = 0.72), RUNX1 mutational status (p = 0.61), FLT3-TKD (p = 0.53), IDH2 mutational status (p = 0.35), IDH1 mutational status (p = 0.34) and age (p = 0.08)
*The median WBC of the whole cohort was 12.7 G/L